Experienced in Bladder Reconstruction

Dr. Bobbie J. Rimel

Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Cedars-Sinai Medical Center
8700 Beverly Blvd, 
West Hollywood, CA 
Offers Telehealth
Experienced in Bladder Reconstruction
Cedars-Sinai Medical Center
8700 Beverly Blvd, 
West Hollywood, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Bobbie Rimel is a Gynecologic Oncologist and an Oncologist in West Hollywood, California. Dr. Rimel is rated as an Experienced provider by MediFind in Bladder Reconstruction. Her top areas of expertise are Ovarian Cancer, Endometrial Cancer, Malignant Mixed Mullerian Tumor, Oophorectomy, and Hysterectomy.

Her clinical research consists of co-authoring 73 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Gynecologic Oncology
Oncology
Obstetrics and Gynecology
Licenses
Obstetrics & Gynecology in WA
Hospital Affiliations
Cedars-Sinai Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

CEDARS-SINAI MEDICAL CENTER
8700 Beverly Blvd, West Hollywood, CA 90048

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 15, 2025
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women With Recurrent, Persistent or Metastatic Endometrial Cancer. A Multi-Arm Trial for Women With Recurrent or Persistent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Drug, Procedure, Biological
Study Phase: Phase 2
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cediranib Maleate, Gemcitabine, Gemcitabine Hydrochloride, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride
Study Phase: Phase 3
Surgical Window of Opportunity Study of Megestrol Acetate Compared With Megestrol Acetate and Metformin for Endometrial Intraepithelial Neoplasia
Surgical Window of Opportunity Study of Megestrol Acetate Compared With Megestrol Acetate and Metformin for Endometrial Intraepithelial Neoplasia
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Other, Procedure, Drug
Study Drugs: Extended Release Metformin Hydrochloride, Megestrol Acetate
Study Phase: Phase 2
Open Label, Phase II Pilot Study of Immune Checkpoint Inhibition With Pembrolizumab in Combination With PARP Inhibition With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancers
Open Label, Phase II Pilot Study of Immune Checkpoint Inhibition With Pembrolizumab in Combination With PARP Inhibition With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancers
Enrollment Status: Active_not_recruiting
Publish Date: May 29, 2025
Intervention Type: Drug
Study Drugs: Pembrolizumab, Olaparib
Study Phase: Phase 2
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
A Randomized, Double-blind, Phase 3 Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 13, 2025
Intervention Type: Drug
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 3
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b
Enrollment Status: Active_not_recruiting
Publish Date: November 13, 2023
Intervention Type: Drug
Study Drug: Upifitamab rilsodotin
Study Phase: Phase 1/Phase 2
A Phase Ib Safety Run-in and Randomized Phase II, Open-label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of M6620 in Combination With Avelumab and Carboplatin in Comparison to Standard of Care Therapy in Participants With PARPi-resistant Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
A Phase Ib Safety Run-in and Randomized Phase II, Open-label Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of M6620 in Combination With Avelumab and Carboplatin in Comparison to Standard of Care Therapy in Participants With PARPi-resistant Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Enrollment Status: Completed
Publish Date: November 13, 2020
Intervention Type: Drug
Study Phase: Phase 1
View 7 Less Clinical Trials

73 Total Publications

The impact of JAK1 pathogenic variants and MHC-I expression on response to immune checkpoint inhibition in endometrial cancer.
The impact of JAK1 pathogenic variants and MHC-I expression on response to immune checkpoint inhibition in endometrial cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 04, 2025
Similar Doctors
Advanced in Bladder Reconstruction
Dr. Alan C. Schlaerth
Gynecologic Oncology | Obstetrics and Gynecology
Advanced in Bladder Reconstruction
Dr. Alan C. Schlaerth
Gynecologic Oncology | Obstetrics and Gynecology
300 W Hungtington Dr, 
Arcadia, CA 
 (19.9 miles away)
626-898-8198
Languages Spoken:
English
See accepted insurances

Alan Schlaerth is a Gynecologic Oncologist and an Obstetrics and Gynecologist in Arcadia, California. Dr. Schlaerth is rated as a Distinguished provider by MediFind in Bladder Reconstruction. His top areas of expertise are Endometrial Cancer, Malignant Mixed Mullerian Tumor, Endometrial Stromal Sarcoma, Oophorectomy, and Vaginectomy.

Advanced in Bladder Reconstruction
Dr. Ramin Mirhashemi
Oncology
Advanced in Bladder Reconstruction
Dr. Ramin Mirhashemi
Oncology
23600 Telo Avenue, Suite 250, 
Torrance, CA 
 (18.4 miles away)
310-375-8446
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Ramin Mirhashemi is an Oncologist in Torrance, California. Dr. Mirhashemi is rated as a Distinguished provider by MediFind in Bladder Reconstruction. His top areas of expertise are Ovarian Carcinosarcoma, Malignant Mixed Mullerian Tumor, Sertoli-Leydig Cell Tumor, Ureteral Reconstruction, and Bladder Reconstruction. Dr. Mirhashemi is currently accepting new patients.

Experienced in Bladder Reconstruction
Dr. Soroush A. Ramin
Oncology | Urology
Experienced in Bladder Reconstruction
Dr. Soroush A. Ramin
Oncology | Urology
5901 West Olympic Boulevard, Suite 307, 
Los Angeles, CA 
 (1.8 miles away)
323-939-3669
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Soroush Ramin is an Oncologist and an Urologist in Los Angeles, California. Dr. Ramin is rated as a Distinguished provider by MediFind in Bladder Reconstruction. His top areas of expertise are Enlarged Prostate (BPH), Familial Prostate Cancer, Prostate Cancer, Reconstructive Urology Surgery, and Ureteroscopy. Dr. Ramin is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rimel's expertise for a condition
ConditionClose
View All 7 Distinguished Conditions
View All 7 Advanced Conditions
View All 48 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile